Ajay Manhapra1,2,3, Albert J Arias1,3, Jane C Ballantyne4. 1. a VA New England Mental Illness Research and Education Center , West Haven , Connecticut , USA. 2. b Advanced Pact Pain Clinic, VA Hampton Medical Center , Hampton , Virginia , USA. 3. c Department of Psychiatry , Yale School of Medicine , New Haven , Connecticut , USA. 4. d Department of Anesthesiology and Pain Medicine , University of Washington School of Medicine , Seattle , Washington , USA.
Abstract
BACKGROUND: In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids. As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain control, functional decline, psychiatric instability, aberrancies and misuse, these issues may often worsen with opioid tapering. Currently, a clear explanation and practical guidance on how to manage this perplexing clinical scenario is lacking. METHODS: We offer a commentary with our perspective on possible mechanisms involved in this clinical phenomena and offer practical management guidance, supported by available evidence. RESULTS: It is not well recognized that allostatic opponent process involved in development of opioid dependence can cause worsening pain, functional status, sleep and psychiatric symptoms over time, and significant fluctuation of pain and other affective symptoms due to their bidirectional dynamic interaction with opioid dependence ('affective dynamism'). These elements of complex persistent dependence (CPD), the grey area between simple dependence and addiction, can lead to escalating and labile opioid need, often generating aberrant behaviors. Opioid tapering, a seemingly logical intervention in this situation, may lead to worsening of pain, function and psychiatric symptoms due to development of protracted abstinence syndrome. We offer practicing clinicians management principles and practical guidance focused on management of CPD in addition to chronic pain in these difficult clinical scenarios. CONCLUSION: Awareness of the science of the neuroplasticity effects of repeated use of opioids is necessary to better manage these patients with complex challenges.
BACKGROUND: In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids. As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain control, functional decline, psychiatric instability, aberrancies and misuse, these issues may often worsen with opioid tapering. Currently, a clear explanation and practical guidance on how to manage this perplexing clinical scenario is lacking. METHODS: We offer a commentary with our perspective on possible mechanisms involved in this clinical phenomena and offer practical management guidance, supported by available evidence. RESULTS: It is not well recognized that allostatic opponent process involved in development of opioid dependence can cause worsening pain, functional status, sleep and psychiatric symptoms over time, and significant fluctuation of pain and other affective symptoms due to their bidirectional dynamic interaction with opioid dependence ('affective dynamism'). These elements of complex persistent dependence (CPD), the grey area between simple dependence and addiction, can lead to escalating and labile opioid need, often generating aberrant behaviors. Opioid tapering, a seemingly logical intervention in this situation, may lead to worsening of pain, function and psychiatric symptoms due to development of protracted abstinence syndrome. We offer practicing clinicians management principles and practical guidance focused on management of CPD in addition to chronic pain in these difficult clinical scenarios. CONCLUSION: Awareness of the science of the neuroplasticity effects of repeated use of opioids is necessary to better manage these patients with complex challenges.
Authors: Richard D Blondell; Lisham Ashrafioun; Christina M Dambra; Elisa M Foschio; Amy L Zielinski; Daniel M Salcedo Journal: J Addict Med Date: 2010-09 Impact factor: 3.702
Authors: Caleb J Banta-Green; Joseph O Merrill; Suzanne R Doyle; Denise M Boudreau; Donald A Calsyn Journal: Drug Alcohol Depend Date: 2009-05-26 Impact factor: 4.492
Authors: Ajay Manhapra; Mark D Sullivan; Jane C Ballantyne; R Ross MacLean; William C Becker Journal: J Gen Intern Med Date: 2020-11-06 Impact factor: 5.128
Authors: Evelyn T Chang; Rebecca S Oberman; Amy N Cohen; Stephanie L Taylor; Elisa Gumm; Aram S Mardian; Shawn Toy; Araceli Revote; Britney Lewkowitz; Elizabeth M Yano Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128
Authors: Hsien-Yen Chang; Noa Krawczyk; Kristin E Schneider; Lindsey Ferris; Matthew Eisenberg; Tom M Richards; B Casey Lyons; Kate Jackson; Jonathan P Weiner; Brendan Saloner Journal: Drug Alcohol Depend Date: 2019-06-07 Impact factor: 4.492
Authors: Pooja Lagisetty; Claire Garpestad; Angela Larkin; Colin Macleod; Derek Antoku; Stephanie Slat; Jennifer Thomas; Victoria Powell; Amy S B Bohnert; Lewei A Lin Journal: Drug Alcohol Depend Date: 2021-02-13 Impact factor: 4.492
Authors: Benjamin A Howell; Erica A Abel; Dongchan Park; Sara N Edmond; Leah J Leisch; William C Becker Journal: J Gen Intern Med Date: 2020-11-11 Impact factor: 5.128